Phase 1 trial of Ruxolitinib combined with Nivolumab in patients relapsed/refractory Hodgkin lymphoma after failure of check‐point inhibitor (CPI)

$Phase 1 trial of Ruxolitinib combined with Nivolumab in patients relapsed/refractory Hodgkin lymphoma after failure of check‐point inhibitor (CPI)$

Abstract

Open access

Peer reviewed

V. Bachanova, J. Zak, Q. Cao, J. Maakaron, B. Grzywacz, C. Fletcher, S. Ayyappan, M. Hu, S. Desai, M. Felices, …

Hematological oncology, Vol.41(S2), pp.582-582

06/2023

DOI: 10.1002/hon.3164_436

Files and links (1)

url

https://doi.org/10.1002/hon.3164_436View

Published (Version of record) Open Access

Title: Subtitle: Phase 1 trial of Ruxolitinib combined with Nivolumab in patients relapsed/refractory Hodgkin lymphoma after failure of check‐point inhibitor (CPI)
Creators: V. Bachanova - University of Minnesota
J. Zak - Scripps Research Institute
Q. Cao - University of Minnesota
J. Maakaron - University of Minnesota
B. Grzywacz - University of Minnesota
C. Fletcher - University of Wisconsin–Madison
S. Ayyappan - University of Iowa
M. Hu - University of Minnesota
S. Desai - University of Minnesota
M. Felices - University of Minnesota
U. Farooq - University of Iowa
J. R. Teijaro - Scripps Research Institute
V. P. Kenkre - University of Wisconsin–Madison
Resource Type: Abstract
Publication Details: Hematological oncology, Vol.41(S2), pp.582-582
DOI: 10.1002/hon.3164_436
ISSN: 0278-0232
eISSN: 1099-1069
Language: English
Date published: 06/2023
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984442223902771

14 Record Views